Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
出版年份 2014 全文链接
标题
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume 10, Issue 8, Pages 2147-2162
出版商
Informa UK Limited
发表日期
2014-06-20
DOI
10.4161/hv.29532
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
- (2014) Maria-Genalin Angelo et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience
- (2014) Maria-Genalin Angelo et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years
- (2012) Tino F. Schwarz et al. JOURNAL OF ADOLESCENT HEALTH
- Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women
- (2012) A.-B. Moscicki et al. VACCINE
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
- (2012) Cecilia M. Roteli-Martins et al. Human Vaccines & Immunotherapeutics
- Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
- (2011) Francis J. Dessy et al. Human vaccines & immunotherapeutics
- Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine
- (2011) Ali Rowhani-Rahbar et al. JOURNAL OF CLINICAL VIROLOGY
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
- (2011) Aimée R. Kreimer et al. JNCI-Journal of the National Cancer Institute
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
- (2011) R. Herrero et al. Cancer Discovery
- Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
- (2010) Dominique Descamps et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women
- (2010) Tiina Petäjä et al. INTERNATIONAL JOURNAL OF CANCER
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women
- (2010) N. De Carvalho et al. VACCINE
- HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
- (2009) Xavier Castellsagué et al. GYNECOLOGIC ONCOLOGY
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆
- (2009) Marie-Pierre David et al. GYNECOLOGIC ONCOLOGY
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
- (2009) Mark Schiffman et al. Infectious Agents and Cancer
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now